Indian drugmaker Lupin announced it aims to seek approval in 2019 for the biosimilar etanercept, which references Amgen's Enbrel. Other early-stage biosimilars in the company's pipeline include ranibizumab, pegfilgrastim, filgrastim, denosumab, pertuzumab and afliberept.
Sign up for Specialty Pharmacy SmartBrief
News affecting the specialty pharmacy industry
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.